American Society of Transplantation
 
Sanofi Genzyme
Takeda Pharmaceuticals, North America
Discover Dosing Options Following Kidney Transplant
Veloxis Pharmaceuticals®
 
Promoted by Veloxis Pharmaceuticals
 
Are you looking for an immunosuppression regimen for kidney transplant patients that allows you to consider their needs? You have dosing options for helping patients achieve adequate immunosuppression. 
Discover More About Dosing
Advertisement
 
AST News
  
On behalf of the AST, the European Society for Organ Transplantation (ESOT), and The Transplantation Society (TTS), we are excited to announce that registration is officially open for the International Transplantation Science Meeting 2025. 
 
ITS 2025 marks the fourth tri-society event in this global collaboration, bringing together top experts, early-career researchers, and transplant professionals worldwide. This meeting offers an exciting forum to explore cutting-edge basic and translational science in and beyond the field of transplantation.
Fellows Symposium on Transplantation
Know an early-career professional or student interested in transplantation? Encourage them to check out the AST Fellows Symposium! This unique program offers expert-led sessions and valuable networking with leaders in the field. It’s a great opportunity for fellows, residents, pharmacists, nurses, and students to explore career paths in transplant and build lasting connections.
New in Expert’s Corner: Managing VZV Exposure
Kamada Pharmaceuticals®
Kamada Expert’s Corner presents an educational module featuring case scenarios on varicella-zoster virus (VZV) exposure in high-risk patients.
Explore expert-guided examples that simulate clinical decision-making in immunocompromised populations.
Visit Kamada’s Expert’s Corner
Advertisement
 
 
  
We're excited to offer a special giveaway in support of the Fellows Symposium on Transplantation! Each year, the AST empowers the next generation of transplant professionals through travel grants, making this essential educational experience accessible to emerging talent.
 
How to Enter
 
Now through September 18: Every $10 donation to Fund a Fellow = 1 entry to win our incredible prize package! Donate $100 and you’ll receive 12 entries (2 bonus entries!).

Prize Package Includes:
  • Exclusive AST swag bag packed with official AST merchandise
  • (2) $25 gift cards for Restaurant.com
  • A curated package and tasting room experience for four at the Bonita Bonita tasting room in Downtown Napa (Nikki and Brie Bella’s Winery!)
Your contribution directly funds travel opportunities for the transplant professionals who will lead our field tomorrow.
Transplant Community Survey on the Pre-Transplant Mortality Ratio Metric
This "Understanding the Impact of the Pre-Transplant Mortality Ratio Metric Implementation" survey focuses on how transplant professionals perceive and respond to the recently implemented pre-transplant mortality ratio metric by UNOS. The goal is to assess how the metric has influenced transplant center practices, particularly in patient listing and organ utilization.
Veloxis Pharmaceuticals
 
OPTN Public Comment
The OPTN summer public comment period began on August 27 and will run through October 1. You can find the proposals the OPTN released for comment this cycle on the OPTN website.
Survey on Family Leave Practices for Transplant Professionals
This 10-minute survey is part of an ongoing AST Women’s Health Community of Practice (WHCOP) effort to better understand and improve support for transplant professionals when it comes to family leave and childrearing. The survey is expected to take less than 10 minutes to complete and will help with understanding the current practices and beliefs surrounding pregnancy and parental leave for transplant professionals. Responses will be used in research to identify gaps, inform best practices, and guide future policy and institutional recommendations to better support the transplant workforce.
The AST is proud to recognize this year’s Fellows of the American Society of Transplantation (FAST). This honorary designation is awarded to members who have demonstrated exceptional commitment to the field of transplantation and outstanding service to the AST.
 
We celebrate the 2025 recipients for their dedication, leadership, and contributions that continue to advance our mission and strengthen the transplant community.
 
Apellis Pharmaceuticals
Transplant Genomics
Updates on Efforts and Resources Related to Transplant Nephrology Training
In fall 2024, the ACGME approved the application from the joint ASN-AST Task Force to recognize transplant nephrology as an accredited subspecialty of nephrology. By supporting a broad and nationwide adoption of uniformly rigorous transplant nephrology training, ASN and AST hope to improve the quality of care provided to patients in both the pre-and post-transplant phases.

A webpage has been created to share ongoing updates and resources related to this new accreditation.
New AJT Article: Transplant Recipients Share Perspectives on Immunosuppressant Needs
Last year, with your support, AST conducted a national patient survey that received nearly 10,000 responses from transplant recipients. The goal: to better understand perceptions of unmet immunosuppressant needs. The findings from this important research have now been published in the American Journal of Transplantation.
Share Your Perspective: Transplant Access and the Criminal Justice System
The AST Psychosocial and Ethics COP (PSECOP) is conducting a short survey to better understand transplant professionals’ perspectives on transplantation for patients who are incarcerated or involved in the criminal justice system. The results will help inform future policies and practices to improve care for this population.
 
The survey takes just 5–10 minutes to complete and is open to transplant professionals (coordinators, social workers, ILDAs, physicians, etc.) currently working at a U.S. transplant center. Please feel free to share the link with colleagues.
 
 
Questions? Contact the research team at emorytransplantresearch@emory.edu or reach out to Principal Investigator Megan Urbanski, PhD, MSW at megan.urbanski@emory.edu. This study has been approved by the Emory University Institutional Review Board.
AST Public Policy Form
The AST developed a survey aimed at soliciting your perspectives on legislative and regulatory issues that significantly influence both patient care and professional practice. Our goal is to establish a platform for our membership to share their invaluable ideas and perspectives and actively engage with the Public Policy Committee and AST leadership. We look forward to your input as we navigate the dynamics of our ever-evolving landscape of transplant care and practice.
Natera
 
 
Sanofi Genzyme
Key Articles in Transplantation
Impact of GLP-1 and GLP-1/GIP Receptor Agonist Weight Loss Post-Lung Transplant on Lung Allograft Function
Source: Wiley Online Library
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GLP-1/glucose dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) use is becoming increasingly common, but there are little data on their use after lung transplantation. Furthermore, obesity is a known cause of lung function decline after lung transplant, but whether weight loss experienced while on these medications leads to improved lung allograft function has not been investigated.
Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single-Center Experience
Source: Wiley Online Library
Extracorporeal photopheresis (ECP) has gained recognition as a valuable adjunctive antirejection therapy, particularly in heart-transplantation (HT) patients at elevated risk for rejection or those experiencing recurrent antibody-mediated rejection (AMR) despite appropriate treatment. We evaluated the safety and clinical effects of ECP in HT recipients with high immunologic risk.
Veloxis Pharmaceuticals
 
ABO-incompatible heart transplants in children aged 2-9 years: a new paradigm in transplant?
Source: The Journal of Heart and Lung Transplantation
Paediatric heart transplantation remains hampered by the limited availability of donor organs. The introduction of ABO-incompatible (ABOi) heart transplantation for infants in the early 2000s expanded the donor pool for individual candidates. Nonetheless, concerns remain about ABOi heart transplantation in children aged over 2 years and it has not been routinely adopted. At our centre we have considered candidates aged 2-9 years for ABOi donors if isohaemagglutinin titres were 1:32 or less. We report the outcomes of those who received an ABOi heart transplant. Furthermore, as all transplant-listed children in this age group were tested for isohaemagglutinins, the potential for ABOi transplant was investigated.
Looking for Immunosuppression Data?
Veloxis Pharmaceuticals®
 
Promoted by Veloxis Pharmaceuticals

Efficacy and safety are important when it comes to immunosuppression after kidney transplantation. Explore clinical data to learn more about the efficacy and safety of your immunosuppression options. 
Explore the Clinical Data
Advertisement
 
 
Transition of Care of Kidney Recipients from Transplant Centers to Referring Nephrologists: Report from the American Society of Transplantation Controversies Conference
Source: American Journal of Kidney Diseases
The expanding number of surviving kidney transplant patients, driven in part by federal initiatives to increase transplant access for patients with advanced CKD, has strained the capacity of the existing transplant nephrology workforce to manage longer-term post-transplant recipients. As patients are living longer with working allografts, the need for effective long-term management has become very important. This can only be achieved by closer collaboration between transplant centers and referring nephrologists. There is, therefore, a great need for closer involvement of referring nephrologists in providing care for this medically complex patient population, necessitating ongoing bidirectional communication with transplant centers. The American Society of Transplantation Kidney Pancreas Community of Practice organized a Controversies Conference in October 2022 to identify major challenges and propose guidance for collaborative, safe and standardized care transition and longitudinal management of this population.
Naylor Association Solutions